Frontiers in Molecular Neuroscience (Jan 2022)
Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System
- Benjamin Deckmyn,
- Benjamin Deckmyn,
- Benjamin Deckmyn,
- Benjamin Deckmyn,
- Benjamin Deckmyn,
- Dorothée Domenger,
- Dorothée Domenger,
- Dorothée Domenger,
- Dorothée Domenger,
- Chloé Blondel,
- Chloé Blondel,
- Chloé Blondel,
- Chloé Blondel,
- Sarah Ducastel,
- Sarah Ducastel,
- Sarah Ducastel,
- Sarah Ducastel,
- Emilie Nicolas,
- Emilie Nicolas,
- Emilie Nicolas,
- Emilie Nicolas,
- Emilie Dorchies,
- Emilie Dorchies,
- Emilie Dorchies,
- Emilie Dorchies,
- Emilie Caron,
- Julie Charton,
- Julie Charton,
- Julie Charton,
- Emmanuelle Vallez,
- Emmanuelle Vallez,
- Emmanuelle Vallez,
- Emmanuelle Vallez,
- Benoit Deprez,
- Benoit Deprez,
- Benoit Deprez,
- Jean-Sébastien Annicotte,
- Sophie Lestavel,
- Sophie Lestavel,
- Sophie Lestavel,
- Sophie Lestavel,
- Anne Tailleux,
- Anne Tailleux,
- Anne Tailleux,
- Anne Tailleux,
- Christophe Magnan,
- Christophe Magnan,
- Bart Staels,
- Bart Staels,
- Bart Staels,
- Bart Staels,
- Kadiombo Bantubungi,
- Kadiombo Bantubungi,
- Kadiombo Bantubungi,
- Kadiombo Bantubungi
Affiliations
- Benjamin Deckmyn
- EGID, U1011, University of Lille, Lille, France
- Benjamin Deckmyn
- Inserm, U1011, Lille, France
- Benjamin Deckmyn
- CHU Lille, Lille, France
- Benjamin Deckmyn
- Institut Pasteur de Lille, Lille, France
- Benjamin Deckmyn
- Laboratory of Lille Catholic Hospitals, Medical Biology Department, Lille Catholic University, Lille, France
- Dorothée Domenger
- EGID, U1011, University of Lille, Lille, France
- Dorothée Domenger
- Inserm, U1011, Lille, France
- Dorothée Domenger
- CHU Lille, Lille, France
- Dorothée Domenger
- Institut Pasteur de Lille, Lille, France
- Chloé Blondel
- EGID, U1011, University of Lille, Lille, France
- Chloé Blondel
- Inserm, U1011, Lille, France
- Chloé Blondel
- CHU Lille, Lille, France
- Chloé Blondel
- Institut Pasteur de Lille, Lille, France
- Sarah Ducastel
- EGID, U1011, University of Lille, Lille, France
- Sarah Ducastel
- Inserm, U1011, Lille, France
- Sarah Ducastel
- CHU Lille, Lille, France
- Sarah Ducastel
- Institut Pasteur de Lille, Lille, France
- Emilie Nicolas
- EGID, U1011, University of Lille, Lille, France
- Emilie Nicolas
- Inserm, U1011, Lille, France
- Emilie Nicolas
- CHU Lille, Lille, France
- Emilie Nicolas
- Institut Pasteur de Lille, Lille, France
- Emilie Dorchies
- EGID, U1011, University of Lille, Lille, France
- Emilie Dorchies
- Inserm, U1011, Lille, France
- Emilie Dorchies
- CHU Lille, Lille, France
- Emilie Dorchies
- Institut Pasteur de Lille, Lille, France
- Emilie Caron
- Inserm UMR-S 1172, Lille, France
- Julie Charton
- Institut Pasteur de Lille, Lille, France
- Julie Charton
- Inserm U1177, Lille, France
- Julie Charton
- Drugs and Molecules for Living Systems, U1177, University of Lille, Lille, France
- Emmanuelle Vallez
- EGID, U1011, University of Lille, Lille, France
- Emmanuelle Vallez
- Inserm, U1011, Lille, France
- Emmanuelle Vallez
- CHU Lille, Lille, France
- Emmanuelle Vallez
- Institut Pasteur de Lille, Lille, France
- Benoit Deprez
- Institut Pasteur de Lille, Lille, France
- Benoit Deprez
- Inserm U1177, Lille, France
- Benoit Deprez
- Drugs and Molecules for Living Systems, U1177, University of Lille, Lille, France
- Jean-Sébastien Annicotte
- CNRS UMR 8199, Lille, France
- Sophie Lestavel
- EGID, U1011, University of Lille, Lille, France
- Sophie Lestavel
- Inserm, U1011, Lille, France
- Sophie Lestavel
- CHU Lille, Lille, France
- Sophie Lestavel
- Institut Pasteur de Lille, Lille, France
- Anne Tailleux
- EGID, U1011, University of Lille, Lille, France
- Anne Tailleux
- Inserm, U1011, Lille, France
- Anne Tailleux
- CHU Lille, Lille, France
- Anne Tailleux
- Institut Pasteur de Lille, Lille, France
- Christophe Magnan
- 0CNRS UMR 8251, Paris, France
- Christophe Magnan
- 1University Paris Diderot, Paris, France
- Bart Staels
- EGID, U1011, University of Lille, Lille, France
- Bart Staels
- Inserm, U1011, Lille, France
- Bart Staels
- CHU Lille, Lille, France
- Bart Staels
- Institut Pasteur de Lille, Lille, France
- Kadiombo Bantubungi
- EGID, U1011, University of Lille, Lille, France
- Kadiombo Bantubungi
- Inserm, U1011, Lille, France
- Kadiombo Bantubungi
- CHU Lille, Lille, France
- Kadiombo Bantubungi
- Institut Pasteur de Lille, Lille, France
- DOI
- https://doi.org/10.3389/fnmol.2021.808603
- Journal volume & issue
-
Vol. 14
Abstract
The nuclear bile acid (BA) receptor farnesoid X receptor (FXR) is a major regulator of metabolic/energy homeostasis in peripheral organs. Indeed, enterohepatic-expressed FXR controls metabolic processes (BA, glucose and lipid metabolism, fat mass, body weight). The central nervous system (CNS) regulates energy homeostasis in close interaction with peripheral organs. While FXR has been reported to be expressed in the brain, its function has not been studied so far. We studied the role of FXR in brain control of energy homeostasis by treating wild-type and FXR-deficient mice by intracerebroventricular (ICV) injection with the reference FXR agonist GW4064. Here we show that pharmacological activation of brain FXR modifies energy homeostasis by affecting brown adipose tissue (BAT) function. Brain FXR activation decreases the rate-limiting enzyme in catecholamine synthesis, tyrosine hydroxylase (TH), and consequently the sympathetic tone. FXR activation acts by inhibiting hypothalamic PKA-CREB induction of TH expression. These findings identify a function of brain FXR in the control of energy homeostasis and shed new light on the complex control of energy homeostasis by BA through FXR.
Keywords